The results of this study point to a possible advantage of PCSK9 inhibition in the early stages of acute coronary syndrome (ACS), particularly for patients with DM and high PCSK9 levels, by a dual mechanism on both lipid-lowering and inflammation/platelet pathways [57]. The gene discussed is PCSK9; the disease is acute coronary syndrome.